

Accepted Manuscript

Nanoparticles for multi-modality cancer diagnosis: Simple protocol for self-assembly of gold nanoclusters mediated by gadolinium ions

Wenxiu Hou, Fangfang Xia, Gabriel Alfranca, Hao Yan, Xiao Zhi, Yanlei Liu, Chen Peng, Chunlei Zhang, Jesus Martinez de la Fuente, Daxiang Cui



PII: S0142-9612(16)30746-3

DOI: [10.1016/j.biomaterials.2016.12.027](https://doi.org/10.1016/j.biomaterials.2016.12.027)

Reference: JBMT 17876

To appear in: *Biomaterials*

Received Date: 23 September 2016

Revised Date: 11 December 2016

Accepted Date: 24 December 2016

Please cite this article as: Hou W, Xia F, Alfranca G, Yan H, Zhi X, Liu Y, Peng C, Zhang C, de la Fuente JM, Cui D, Nanoparticles for multi-modality cancer diagnosis: Simple protocol for self-assembly of gold nanoclusters mediated by gadolinium ions, *Biomaterials* (2017), doi: 10.1016/j.biomaterials.2016.12.027.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Nanoparticles for multi-modality cancer diagnosis: Simple protocol for self-assembly of gold nanoclusters mediated by gadolinium ions

Wenxiu Hou^{a,b,#}, Fangfang Xia^{a,#}, Gabriel Alfranca^{a,d}, Hao Yan^a, Xiao Zhi^a, Yanlei Liu^{a,b}, Chen Peng^{c*}, Chunlei Zhang^{a*}, Jesus Martinez de la Fuente^{a,d}, Daxiang Cui^{a*}

^aInstitute of Nano Biomedicine and Engineering, Shanghai Engineering Research Centre for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, 800 Dongchuan RD, Shanghai 200240, P.R. China

^bSchool of Biomedical Engineering, Shanghai Jiao Tong University, 800 Dongchuan RD, Shanghai 200240, P.R. China

^cDepartment of Radiology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, P.R. China.

^dInstituto de Ciencia de Materiales de Aragón, Consejo Superior de Investigaciones Científicas/Universidad de Zaragoza, Spain.

[#]These authors equally contributed to this work.

* Corresponding author.

E-mail: dx cui@sjtu.edu.cn

E-mail: cpengrr@tongji.edu.cn

E-mail: chunleizhang@sjtu.edu.cn

1 **ABSTRACT:**

2 It is essential to develop a simple synthetic strategy to improve the quality of
3 multifunctional contrast agents for cancer diagnosis. Herein, we report a time-saving
4 method for gadolinium (Gd^{3+}) ions-mediated self-assembly of gold nanoclusters
5 (GNCs) into monodisperse spherical nanoparticles (GNCNs) under mild conditions.
6 The monodisperse, regular and colloidal stable GNCNs were formed via selectively
7 inducing electrostatic interactions between negatively-charged carboxylic groups of
8 gold nanoclusters and trivalent cations of gadolinium in aqueous solution. In this way,
9 the Gd^{3+} ions were chelated into GNCNs without the use of molecular gadolinium
10 chelates. With the co-existence of GNCs and Gd^{3+} ions, the formed GNCNs exhibit
11 significant luminescence intensity enhancement for near-infrared fluorescence (NIRF)
12 imaging, high X-ray attenuation for computed tomography (CT) imaging and
13 reasonable r_1 relaxivity for magnetic resonance (MR) imaging. The excellent
14 biocompatibility of the GNCNs was proved both *in vitro* and *in vivo*. Meanwhile, the
15 GNCNs also possess unique NIRF/CT/MR imaging ability in A549 tumor-bearing
16 mice. In a nutshell, the simple and safe GNCNs hold great potential for tumor
17 multi-modality clinical diagnosis.

18 **Keywords:** Gold nanoclusters (GNCs) · Gd^{3+} ions · Assembly · Multi-modality
19 imaging · Diagnosis

20

21

22

23

24

25

26

1 **1. Introduction**

2 Nowadays, there is an increasing interest in the development of molecular imaging
3 technology for applications in early-stage cancer imaging diagnosis[1, 2]. Among
4 various imaging modalities, near-infrared fluorescence (NIRF)[3], computed
5 tomography (CT)[4] and magnetic resonance (MR)[5] imaging are three of the most
6 widely used imaging techniques for disease diagnosis. NIRF imaging possesses high
7 sensitivity. But it cannot guarantee an adequate spatial resolution [6]. CT imaging is a
8 time-saving and low cost imaging technique with excellent density and spatial
9 resolution. Despite of high-resolution images of anatomic structures, CT imaging is
10 trapped in soft-tissue imaging applications due to the inadequacy of sensitivity [4].
11 Besides, MR imaging is a non-invasive technique with high sensitivity, good tissue
12 penetration depth, and detailed profile ability of soft-tissues. But it is unable to detect
13 lesions of bone structures [7]. Due to the limitations of the individual imaging technique
14 discussed above, the use of dual mode or multimode imaging is indispensable for
15 comprehensive and accurate cancer diagnosis, especially for early-stage cancer
16 diagnosis [8-10]. To present day, the development of nanoparticle-based contrast agents
17 provide a promising way to integrate the advantages of different imaging techniques for
18 accurate cancer diagnosis and for extending the application scope of molecular
19 imaging[11-14]. Nevertheless, most of the contrast agents used in the clinic are only
20 suitable for single modality imaging. Meanwhile, complicated architectures and
21 synthetic processes are always required to synthesize multifunctional nanoparticle-based
22 contrast agents for multi-modality cancer diagnosis [11, 15, 16]. Thus, the development
23 of a simple and time-saving protocol to synthesize a single nanostructure bearing
24 various contrast agents for different imaging modalities would bring a great
25 improvement towards an accurate cancer diagnosis.

26 Among the numerous nanoparticles described nowadays [12, 13, 17, 18], the noble
27 metal nanoclusters (NCs) are ultrasmall nanoparticles (with a core size smaller than 2
28 nm) with well-defined sizes, components and charges[19, 20]. They possess strong
29 luminescence and enhanced catalytic activity which make them especially attractive in

1 biomedical areas for biosensing[21], bioimaging [22, 23], and therapy [24, 25].
2 Generally speaking, polymers, dendrimers, biological molecules or polyelectrolytes are
3 the main templates used to synthesize NCs in solution [24, 26-28]. Glutathione
4 (GSH)-capped gold nanoclusters (GNCs) are one kind of noble metal nanoclusters that
5 are synthesized using glutathione as thiolate ligand, and can be denoted as $Au_n(SG)_m$
6 (where n is the number of gold atoms, and m is the number of glutathione molecules)
7 [29-31]. The GNCs composed of a dozen to about a hundred gold atoms possess many
8 advantages for biomedical applications, such as excellent biocompatibility, good water
9 solubility, faster clearance by normal tissues, longer retention time in the tumor, and
10 easily functionalized surface ligands [26, 32, 33]. Moreover, the intrinsic characteristics
11 of GNCs, red-near-infrared fluorescence, large two-photon excitation and excellent
12 X-ray attenuation, make them highly suitable for both *in vitro* and *in vivo* NIRF and CT
13 imaging [29, 33-35]. Therefore, the GNCs may have a great potential for multi-modality
14 cancer diagnosis. Nowadays, the lanthanide ion Gd^{3+} based contrast agents have been
15 widely studied for cancer diagnosis [16, 36, 37]. But the development of sensitive,
16 biocompatible, and stable Gd^{3+} -based contrast agents without the use of molecular
17 gadolinium chelates still remains as an interesting approach and great challenge. Based
18 on the qualities of GNCs and lanthanide Gd^{3+} ions, an exciting methodology for
19 biomedical applications could be development of an effective and simple method to
20 assemble GNCs and Gd^{3+} ions into a single multifunctional spherical nanoparticle for
21 cancer multi-modality imaging. According to a previous report [38], the GNCs could be
22 assembled into monodisperse and uniform spheres via selectively inducing interaction
23 of electrons between divalent cations and negatively-charged GNCs. In this scenario,
24 the GNCs can sever as a new family of ion mimics (“nanoions”) in aqueous solution
25 where the self-assemble process is analogous to the theory of formation of ionic crystals
26 from real ions. Using the above theory, the hydrophilic GNCs could be assembled into
27 monodisperse spherical shapes via the strong interaction of electrons between
28 negatively-charged GNCs and trivalent counter cations of gadolinium. If properly
29 implemented, this method to combine GNCs and Gd^{3+} ions would be a simple and
30 time-saving approach to assemble them into a single nanoparticle for multi-modality

1 tumor imaging.

2 Herein, we report the assembly of gold nanoclusters into monodisperse regular and
3 stable spherical nanoparticles (GNCNs) by a selective electrostatic interaction for
4 enhanced tumor multi-modality imaging (scheme 1). This simple and time-saving
5 electrostatic interaction occurs between negatively-charged carboxylic groups on the
6 gold nanoclusters and trivalent cations of gadolinium (Gd^{3+}) in aqueous solution under
7 mild conditions. The assembly behavior only occurs when the ratio of Gd^{3+} ions and
8 carboxylate groups exceeds certain threshold values. Such behavior is different from the
9 random aggregation of colloidal nanoparticles by counter ions. With the co-existence of
10 GNCs and Gd^{3+} ions, the formed GNCNs exhibit an enhanced fluorescence, high X-ray
11 attenuation and reasonable r_1 relaxivity. All of these properties ensure that GNCNs
12 could be used as NIRF/CT/MR multi-modality imaging contrast agents for accurate
13 diagnosis of different types of tumor. The physicochemical properties of the synthesized
14 GNCNs were extensively characterized via various techniques. In addition, both *in vitro*
15 and *in vivo* experiments are carried out to carefully evaluate the biocompatibility,
16 cellular uptake efficacy and tumor NIRF/CT/MR multi-modality imaging performance.
17 We believe that the multifunctional spherical GNCNs are novel, simple and safe
18 nanoparticles, which hold great potential for cancer NIRF/CT/MR multi-modality
19 clinical diagnose.

20 **2. Materials and methods**

21 *2.1. Materials*

22 Tetrabutylammonium borohydride (TBAB; 95%) and Gadolinium chloride
23 hexahydrate ($GdCl_3 \cdot 6H_2O$) were obtained from Aladdin Reagent Co. Ltd. (Shanghai
24 China). Sephadex G-150 was purchased from Pharmacia (Uppsala, Sweden).
25 3-[4,5-Dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide (MTT), Gold chloride
26 trihydrate ($HAuCl_4 \cdot 3H_2O$, 99%) and Hoechst 33342 were received from Sigma
27 Chemical Corporation (St Louis, USA). The reagents related to cell culture were
28 obtained from Hyclone. Ultrapure water with resistivity of 18.2 $M\Omega$ was used in the

1 preparation of all aqueous solutions.

2 2.2. *Synthesis of red-emitting GNCs*

3 The procedure to synthesize red-emitting GNCs is similar to our previous study
4 [24]. Briefly, the freshly prepared HAuCl₄ (5 mL, 0.02 M) and GSH (2 mL, 0.15 M)
5 were diluted with 87 mL cold deionized water under vigorous stirring for 3 min. Then
6 the mixture was added with icy cold TBAB solution (6 mL, 0.186 M) under a quickly
7 vigorous stirring for 5 min. After the mixture was maintained for 2 h without vigorous
8 stirring in ice bath, 1M HCl was added to adjust the pH of the reaction to about 3.0.
9 Then the insoluble Au(I)-thiolate complex were separated by centrifugation. After
10 another 12 h incubation of the mixture in ice bath, the supernatant was added with NaCl
11 (to about 10×10^{-3} M) and cold methyl alcohol to collect the precipitates. The
12 precipitates were dialyzed for three days against ultrapure water to obtain the GNCs.

13 2.3. *Gd (III) ions-induced assembly of red-emitting GNCs*

14 Before the reaction, the above prepared GNCs (1.25 mg/mL) and the GdCl₃·6H₂O
15 in specific concentration were dissolved in the aqueous solution, respectively. Then the
16 pH of the each solution was adjusted to about 6.5. The GdCl₃ solution was freshly
17 prepared and sonicated for 3 min by an ultrasonicator at 100 W before used. Taking
18 $R_{[Gd^{3+}]/[GSH]}=0.08$ as an example, 0.25mL of 0.73 mM GdCl₃ aqueous solution was
19 added dropwise into GNCs aqueous solution (1.25 mg/mL,1mL) under stirring and
20 maintained at 30 °C for 3 h. The gel filtration method (Sephadex G-150 column
21 equilibrated with the ultrapure water) was used to purify the assembled GNCs (GNCNs).
22 Assembly of GNCs by Gd³⁺ ions in other concentration was also synthesized in the
23 similar steps.

24 2.4. Characterization

25 The size and the morphology of GNCNs were evaluated by transmission electron
26 microscopy (TEM), high resolution TEM (HR-TEM) and field emission scanning
27 electron microscopy (SEM). The composition of GNCNs was measured by
28 energy-dispersive X-ray spectroscopy (EDX) and scanning transmission electron

1 microscopy (STEM). PL spectra were characterized by a Hitachi FL-4600
2 spectrofluorometer. UV-vis spectra were tested with a Varian Cary 50
3 spectrophotometer (Varian Inc., USA). The size and ζ -potential of GNCNs were
4 estimated by a Nicomp 380 ZLS Zeta potential/Particle sizer (PSS Nicomp, USA).
5 Moreover, the aqueous solution of GNCs, GNCNs, Omnipaque and Gd-DTPA were
6 prepared into Eppendorf tubes (1.5 mL) with different concentrations before CT or MR
7 imaging. The dual-source CT system (SOMATOM Definition Flash, Siemens, Erlangen,
8 Germany) was used to perform the CT scanning with the parameters set to 100 kV, 80
9 mA, and a slice thickness of 0.625 mm. Hounsfield units (HU) for the regions of
10 interest were used to determine the contrast enhancement of each sample and each
11 sample was measured for 3 times. The T1 relaxation times of the GNCNs and Gd-DTPA
12 with different Gd^{3+} concentrations was performed using a 0.5T NMI20-Analyst NMR
13 Analyzing and Imaging system (Shanghai Niumag Corporation, China) with 0.6 mm
14 section thickness, TE = 160 ms, TR = 600 ms, 156 mm \times 156 mm point resolution and
15 one time excitation. The T1 relaxivity was measured by a linear fitting of the T1
16 relaxation time ($1/T1$) as a function of the Gd^{3+} ions concentration.

17 2.5. Cell culture

18 The A549 cells (human non-small cell lung cancer cell) were chosen as modal cells
19 in this study. DMEM medium with 10% FBS was used to incubate A549 cells at 37 °C
20 with 5% CO₂.

21 2.6. Cytotoxicity and hemolysis assay

22 *MTT assay*, The A549 cells viability was tested by the MTT assay to evaluate the
23 cytotoxicity of the GNCNs. Briefly, the cells were seeded into a 96-well plate (5×10^3
24 cells/well) and incubated in medium for 24 h. After that, the fresh medium containing
25 GNCNs at different Au concentrations or PBS (control group) were used to replace the
26 above medium, respectively. After 24 h and 48 h incubation, the medium was added
27 with MTT (5 mg/mL, 20 mL) and maintained incubation for another 4 h, respectively.
28 The cell viability was assessed refer to the previous report.[39]

1 *Apoptosis assay*, in briefly, A549 cells at 2.0×10^5 cells/well were seeded in 6-well
2 plates for 24 h. Then, the cells were incubated with GNCNs at different Au
3 concentrations or PBS (control group) for 24 h. The distributions of necrotic or
4 apoptotic cells induced by GNCNs were measured on the basis of the manufacturer's
5 protocol of Annexin V-FITC/PI apoptosis detection kit. The flow cytometry (BD
6 FACSCalibur, BD Biosciences, USA) was used to measure the apoptosis of GNCNs
7 treated cells. The data were analyzed by FlowJo 7.6 software.

8 *Hemolysis assay*, the fresh human blood was centrifuged at 1000 rpm for 10 min to
9 remove the supernatant. Then, the blood was washed with PBS for 5 times to acquire
10 the red blood cells (HRBCs). The HRBCs suspension (0.1mL) was diluted into 0.9 mL
11 PBS (negative control group), 0.9 ml water (positive control group), or 0.9 mL GNCNs
12 PBS solution at different Au concentrations (22-550 μ M), respectively. The mixtures
13 were reacted at room temperature for 2 h, after a gentle shaking. After that, the mixtures
14 were centrifuged at 10000 rpm for 1 min. The absorbance of the supernatants at 541nm
15 and the photos of the mixtures were recorded to measure the hemolysis of GNCNs. The
16 hemolysis percentages = (OD541 nm of the experiment group - OD541 nm of the
17 negative control group)/(OD541 nm of the positive control - OD541 nm of the negative
18 control group) \times 100%.

19 2.7. Cellular uptake assay

20 *Confocal microscopy experiments*, A549 cells (2.0×10^4 cells/well) were seeded in
21 coverglass in 24-well plates. After 24 h incubation, the cells were co-incubation with
22 GNCs or GNCNs at Au concentration of 550 μ M for 4 h and 10 h, respectively. After
23 two times washed with PBS, the cells were fixed by the 2.5% glutaraldehyde for 30 min
24 at 4 °C. Then Hoechst 33342 was used to stain nuclei at room temperature for 15 min.
25 The nuclei was detected by the blue diode 405 nm laser. And the GNCNs and GNCs
26 were excited at 620 nm on the TCS SP8 confocal laser scanning microscope.

27 *Flow cytometry (FCM) measurements*, A549 cells (2.0×10^5 cells/well) were plated
28 onto 6-well plates and cultured in medium for 24 h. Then, the cells were treated with
29 GNCs or GNCNs at Au concentration of 550 μ M for 4 h and 10 h, respectively. FL3

1 channel was used to measure the amount of GNCs or GNCNs in A549 cells,
2 respectively.

3 *ICP-MS measurements*, similar to the steps of FCM measurements, the A549 cells
4 were collected and then digested by aqua regia before quantifying by ICP-MS. Besides,
5 the A549 cells were also co-incubated with GNCNs or GNCs at different Au
6 concentrations ($[Au] = 0-550\mu M$) for 10 h to test the cell uptake efficiency by ICP-MS.

7 2.8. *In vitro NIRF/CT/MR imaging*

8 Approximately 2×10^6 A549 cells were seeded in 5 mL cell culture flask and then
9 were incubated for 24 h. After that, the cells were co-incubated with 2 mL fresh medium
10 containing GNCNs or GNCs at different Au concentrations ($[Au] = 0-550 \mu M$). After 10
11 h incubation, the cells were resuspended in 100 μL PBS and placed in 1.5 mL
12 Eppendorf tubes. The *in vivo* tumor CT imaging studies were conducted with
13 dual-source CT system. The T1-weighted MR imaging of the A549 cells incubation
14 with the GNCNs was measured by a 3.0 T clinical MR imaging instrument (SOMATON
15 Definition Flash, Siemens, Erlangen, Germany). MR images of A549 cells were
16 acquired with slice thickness = 0.7 mm, TR = 280 ms, TE = 15 ms, 318×314 matrix and
17 80×100 FOV. The signal to noise ratio (SNR) (T1-weighted MRI signal intensity of the
18 tumor area/T1-weighted MRI signal intensity of air area) was calculated to quantify the
19 T1-weighted MRI effect of the GNCNs. For *in vitro* NIRF imaging, A549 cells (5×10^3
20 per well was pelleted in 96-well plates) were incubated with GNCNs or GNCs (at the
21 same Au concentrations for CT/MR imaging) for 10 h. Then, the Bruker In-Vivo F PRO
22 imaging system (Billerica, USA) was used to obtain fluorescence images with
23 excitation: 530/20 nm, emission: 700/30 nm and integration time: 20 s.

24 2.9. *In vivo NIRF/CT/MR imaging*

25 Female and male BALB/c-nude mice (4 weeks of age) were obtained from
26 Shanghai Slac Laboratory Animal Co., Ltd. According to the Institutional Animal Care
27 and Use Committee of Shanghai Jiao Tong University, all animals received care. In the
28 right flank regions of mice, 4×10^6 A549 cells/mouse were subcutaneously injected to

1 establish A549 tumor model. The volume of tumors were allowed to reach $\sim 200 \text{ mm}^3$
2 before the NIRF/CT/ MR imaging.

3 For the CT imaging, the mice were randomly allocated into 2 groups. Mice in
4 group 1 were intravenously injected with GNCs. Mice in group 2 were intravenously
5 injected with GNCNs (both containing 0.11 M Au, 150 μL per mouse). The CT
6 scanning was executed at different time points by using a dual-source CT system. For
7 MR imaging, the mice were given tail intravenous injection with the GNCNs ($[\text{Gd}] =$
8 5mM, 150 μL per mouse). The T1-weighted MR imaging of the mice was carried out by
9 using a 3.0 T clinical MR imaging instrument. Moreover, at preset time points, the
10 fluorescence images were acquired after the mice were intratumoral injected with the
11 GNCs or GNCNs ($[\text{Au}] = 0.11 \text{ M}$, 50 μL per mouse), by using a Bruker In-Vivo F PRO
12 imaging system (Billerica, USA). The mice were sacrificed and the tumors and main
13 organs were extracted for *ex vivo* NIRF imaging at 24 h post-injection,. The Bruker
14 Molecular Imaging Software 7.1 Version was used to quantify the average fluorescence
15 intensity of the excised organs and tumor.

16 2.10. *In vivo* biodistribution of GNCNs

17 For *in vivo* biodistribution studies of GNCNs, the A549 tumor bearing mice were
18 caudal vein injected with GNCNs ($[\text{Au}] = 0.11 \text{ M}$, 150 μL per mouse). After 20 min, 60
19 min and 6 h post injection, the mice were sacrificed and the main organs (heart, spleen,
20 lung, kidney, and liver), blood and tumors were extracted and weighed, respectively.
21 The gold and gadolinium elements content in organs, blood and tumors were analyzed
22 by ICP-OES, after digesting the extracted samples in aqua regia solution overnight.

23 2.11. *In vivo* security evaluation

24 *Blood analysis*, the BALB/c female mice were intravenously injected with GNCNs
25 ($[\text{Au}] = 0.11 \text{ M}$, 300 μL per mouse). The weight was measured for 21 days after
26 intravenous injection. 500 μL of blood was collected and separated before and after 7
27 days and 21 days of intravenous injection, respectively. The indicators of kidney
28 function (creatinine (CREA), urea nitrogen (BUN) and uric acid (UA)) and liver

1 function (lactate dehydrogenase (LDH), alkaline phosphatase (ALP), gamma glutamyl
2 transferase (GGT), total bilirubin (TBIL) and aspartate aminotransferase (AST)) were
3 tested by standard biochemical examination.

4 *For the histochemical analysis*, the main organs (liver, lung, spleen, heart, and
5 kidney) were harvested before and after 21 days of tail intravenous injection of GNCNs.
6 Then hematoxylin and eosin (HE) staining assay were performed to detect the change in
7 morphological features of each organ.

8 *2.12. Statistical analysis*

9 All data were expressed as mean \pm SD (Standard Deviation) of at least three
10 independent experiments unless otherwise specified.

11 **3. Results and discussions**

12 *3.1. Synthesis and characterization of GNCs and GNCNs*

13 The TBAB-reduction method [24, 40] was used to synthesize red-emitting and
14 glutathione (GSH)-capped gold nanoclusters (GNCs), with a main fluorescence peak at
15 652 nm. The monodispersed spherical GNCs (with a GSH-to-Au atom ratio of 0.82) had
16 a diameter of about 2.0 nm (Fig. S1A) and also possessed high GSH content on their
17 surface [24, 29]. It has been reported that the pKa of the glutathione (GSH) moiety was
18 below 4 [41]. Following this statement, all of the surface carboxylic groups would be
19 deprotonated under neutral conditions leading to the GNCs to acquire a negative
20 charged surface [38]. Thus, the positively charged Gd^{3+} ions could bind to the
21 negatively charged GNCs by both strong electrostatic interactions and coordination
22 effects, in aqueous solution [22, 42].

23 Gd^{3+} ions in aqueous solution were added dropwise to the aqueous solution of
24 GNCs in different concentrations to obtain assembled GNCs (GNCNs). The
25 morphology and size of the GNCNs were characterized by TEM. Since the Gd^{3+} ions
26 were electrostatically bound to the carboxyl groups of the GSH on the surface of the
27 GNCs, the size and morphology of the assembled GNCs would depend on the molar

1 ratio of Gd^{3+} ions to GSH (designated as $R_{[\text{Gd}^{3+}]/[\text{GSH}]}$). As shown in the inset in Fig. S1A,
2 when no Gd^{3+} ions were added ($R_{[\text{Gd}^{3+}]/[\text{GSH}]} = 0$), the monodispersed GNCs with
3 spherical shape gave a brownish color to the solution and revealed a good dispersion in
4 aqueous solution. If the $R_{[\text{Gd}^{3+}]/[\text{GSH}]}$ was increased to 0.05, the Gd^{3+} ions began to induce
5 the assembly of the GNCs. Under these conditions, partially assembled GNCs with
6 small spherical shapes appeared in the TEM images (Fig. S1B). Meanwhile, the status
7 of the assembled GNCs solution displayed no visible change (inset in Fig. S1B),
8 compared with that of the free GNCs. This may be attributed to a lack of Gd^{3+} ions,
9 which act as the bridge to induce the assembly of GNCs [38]. Uniformed and
10 monodispersed spherical assembled GNCs were observed in TEM images when
11 $R_{[\text{Gd}^{3+}]/[\text{GSH}]}$ was increased to 0.08 (Fig. S1C). Under these conditions, the solution
12 containing the assembled GNCs revealed a translucent light fawn color and showed
13 excellent water solubility (insets in Fig. S1C). At a $R_{[\text{Gd}^{3+}]/[\text{GSH}]}$ value of 0.11, an
14 aggregation generated from irregularly assembled structures appeared in the TEM
15 images (Fig. S1D). The aqueous solution of the assembled GNCs became turbid and
16 showed tawny color, which confirmed that the aggregations were successfully generated
17 (inset in Fig. S1D). The occurrence of the aggregation was formed by bridging the
18 individual GNCNs together under the condition of excessive Gd^{3+} ions. The size of the
19 assembled GNCs increase with the $R_{[\text{Gd}^{3+}]/[\text{GSH}]}$ value was corroborated by the
20 enhancement of the absorbance value observed by UV-Vis spectroscopy (Fig. S2A) [43].
21 The two main effects of the counter cations influencing on the assembly of GNCs have
22 been recently reported by Yao *et al.*[38] and can be summed up as decrease in the
23 negative charge on the GNCs and the subsequent bridging of the GNCs. This
24 explanation matches with the increase in the zeta potential of the aqueous solution of
25 GNCNs (pH \approx 6.5) with the concentration of Gd^{3+} ions (Fig. S2B). As a consequence, the
26 GNCs were assembled at an optimal $R_{[\text{Gd}^{3+}]/[\text{GSH}]}$ value of 0.08 for their future
27 application in tumor diagnosis.

28 The morphology and composition of assembled GNCs at $R_{[\text{Gd}^{3+}]/[\text{GSH}]}$ of 0.08 were
29 also tested by HR-TEM. As shown in Fig. 1A and B, the diameter of GNCs was about 2
30 nm and they could be plain visualized inside the assembled GNCNs. The SEM images

1 with the corresponding results indicated that the GNCNs were almost uniform spheres
2 with good monodispersity (Fig. 1C and Fig. S3). The narrow hydrodynamic diameter
3 distribution around 200 nm of the GNCNs in aqueous solution measured by DLS (Fig.
4 1D) not only confirmed the results of TEM and SEM but also indicated that the GNCNs
5 may preferentially enter the tumor tissue by the Enhanced Permeability and Retention
6 (EPR) effect [44]. As previously reported, the ultrasmall metal GNCNs can be
7 considered as a new family of ion mimics (“nanoions”) [38]. The high order of
8 regularity of the assembled GNCs may be due to the selectively induced electrostatic
9 interactions in the assembly of the GNCs, which is similar to the formation of ionic
10 crystals from real ions while different from the random aggregation of counter
11 ions-mediated nanoparticles [38]. Moreover, elemental line-scanning EDX and mapping
12 EDX analysis were performed to further demonstrate the chemical composition and the
13 atomic distribution of the GNCNs [45, 46]. Fig. 2A showed a linear distribution of
14 elemental Au and Gd across the diameter of a typical assembly, where the concentration
15 of Au was clearly higher than that of the Gd in the entire region of the GNCNs. In order
16 to further research the elemental spatial distribution of Au and Gd in GNCNs, elemental
17 mapping of EDX analysis was carried out throughout a representative sample of
18 GNCNs, as depicted in Fig. 2A. The two recognizable signals of elemental Au and Gd
19 were distributed uniformly in the whole volume of GNCNs, as shown in Fig. 2B-D. By
20 combining these data with EDX spectrum analysis (Fig. 2E), the exact composition of
21 the spherical assembly was determined. We can infer that the GNCNs were indeed
22 formed by the assimilation of GNCs with Gd^{3+} ions. The fluorescence excitation of the
23 GNCs and GNCNs were depicted in Fig. S4 and Fig. 3A. The addition of Gd^{3+} ions had
24 a strong effect on the physical and chemical properties of the GNCs with an
25 enhancement in the optical luminescence accompanied by a blue shift of the emission
26 peak. The fluorescence intensity of GNCNs at an optimal $R_{[\text{Gd}^{3+}]/[\text{GSH}]}$ of 0.08 was
27 almost 1-fold enhanced when compared with that of the GNCs (Fig. 3A). The increase
28 of the optical luminescence of the GNCNs may be caused by the significantly shortened
29 distance between the GNCs after their assembly, sequentially increasing the
30 *inter-cluster* aurophilic interaction [47, 48] and reducing the non-irradiative relaxation

1 of excited electrons [48, 49]. In contrast, the fluorescence intensity was decreased at a
2 higher $R_{[\text{Gd}^{3+}]/[\text{GSH}]}$ value of 0.11, which may be due to the sedimentation of aggregated
3 nanoparticles [22].

4 *3.2. Stability, cytotoxicity and hemolysis assay of the GNCNs*

5 It is crucial to test the stability of GNCNs before they are used in biomedical
6 applications. Herein, the stability of the nanoparticles was further confirmed by TEM,
7 UV-Vis, and DLS. The hydrodynamic diameter of the GNCNs revealed minor
8 fluctuations within a period of one month, suggesting that the GNCNs have a good
9 colloidal stability and can be stored in aqueous solution without noteworthy
10 disaggregation or aggregation for a relatively long period of time (Fig. 3B). As shown in
11 Fig. S5A, with the exception of a slight change in the smoothness of the surface, there
12 was no observable agglomeration or disaggregation of GNCNs in the TEM images after
13 being stored in aqueous solution for one month, which visually confirmed the stability
14 of the GNCNs. Furthermore, the absorption features of the UV-Vis spectra of GNCNs at
15 different temperatures in aqueous media solution showed no detectable variation (Fig.
16 S5B), indicating that the GNCNs nanoprobe are stable in a temperature range of
17 4-50 °C [50, 51]. Finally, no clear precipitation or state change were observed in the
18 GNCNs solution after being exposed to PBS (pH=7.4) for two weeks (Fig. S5C).
19 Although the results of Z-potential of the GNCNs in aqueous solution was very low, the
20 observed stability of the GNCNs may be due to the surface glutathione endowing the
21 GNCNs with a high steric hindrance. These results proved that GNCNs are stable,
22 which is a basic feature for their future application on the biomedical field.

23 The cytocompatibility of the GNCNs is also a crucial indicator to test their
24 potential for biomedical imaging applications. The cell viability was evaluated by MTT
25 assay to assess the cytocompatibility of the GNCNs (Fig. 4A). In comparison with the
26 control cells incubated with PBS, the viability of A549 cells had no appreciable change
27 after 24 h treatment with the GNCNs in a concentration range of 0-550 μM of Au. After
28 incubation with the GNCNs for 48 h, the GNCNs start to display a slight cytotoxicity at
29 Au concentrations higher than 220 μM . The MTT results inferred that the GNCNs were

1 cytocompatible at the studied concentration. Moreover, the apoptosis assay of A549
2 cells exposed to GNCNs at different Au concentrations was measured by flow
3 cytometry, revealing similar results to those of the MTT assay, as shown in Fig. S6.

4 Hemocompatibility is an important issue in blood-contacting applications of
5 nanoparticles. Hemolysis assays were performed to examine the hemocompatibility of
6 the GNCNs before their use as contrast agents for tumor multi-modality imaging, *in*
7 *vivo* (Fig. 4B). The absorbance at 541 nm of the supernatant in the UV-Vis spectra was
8 measured to quantify the hemolysis percentages of the GNCNs at different Au
9 concentrations (0–550 μM). The GNCNs do not show obvious hemolytic effects at the
10 measured Au concentrations, when compared with the positive control. The results
11 showed that even at the maximum concentration of element Au, the hemolysis
12 percentage of GNCNs is less than the threshold value of 5% with the highest hemolysis
13 percentage reaching 3.15%, suggesting an excellent hemocompatibility in the studied
14 concentration range and enabling the GNCNs to be used for future *in vivo* tumor
15 multi-modality imaging.

16 3.3. T1 MR relaxometry and X-ray attenuation

17 With the co-existence of GNCs and Gd^{3+} ions, the formed GNCNs possess X-ray
18 attenuation and T1 MR relaxivity properties for CT and MR imaging applications,
19 respectively. Herein, the X-ray attenuation property and T1 MR relaxometry of the
20 GNCNs were measured prior to *in vivo* multi-modality imaging studies. The brightness
21 change in the CT images of GNCs, GNCNs and Omnipaque (iodine-based CT contrast
22 agent) in various concentrations of Au or iodine revealed that the CT contrast
23 enhancement was improved with the increase of Au or iodine concentrations (Fig. 5A).
24 It was obvious that the brightness of the CT images and the attenuation intensity of
25 GNCNs were higher than that of free GNCs at the same Au concentrations (Fig. 5B).
26 That may be caused by the existence of Gd^{3+} ions, which probably contribute to a small
27 contrast enhancement of the CT images of GNCNs [52, 53]. Compared with the
28 Omnipaque, the enhanced X-ray attenuation property of GNCNs and GNCs may be
29 caused by the X-ray absorption coefficient of Au is higher than that of I [4]. In addition,

1 with the increase of the concentration of Gd^{3+} ions, a concentration-dependent signal
2 enhancement appeared in the T1-weighted MR images of DTPA-Gd and GNCNs (Fig.
3 5C). It was clear that the signal enhancement intensity of the GNCNs was better than
4 that of the T1 contrast agent Magnevist (DTPA-Gd) at the same Gd^{3+} ions concentration.
5 Simultaneously, the transverse relaxivity (r_1) value of GNCNs was $24.64 \text{ mM}^{-1} \text{ S}^{-1}$,
6 which was about 4.3 times higher than that of the Magnevist ($4.68 \text{ mM}^{-1} \text{ S}^{-1}$), implying
7 a superior contrasting ability of GNCNs in T1-weighted MRI (Fig. 5D). In the GNCNs
8 system, compared with that of the gadolinium chelated in Magnevist, the local
9 concentration of Gd^{3+} ions was increased and the tumbling and rotational rate of Gd^{3+}
10 ions was reduced, which may give a higher relaxivity value to GNCNs than that of the
11 Magnevist [9, 36, 54, 55]. In a word, the GNCNs possess an enhanced fluorescence,
12 reasonable T1 relaxivity and highly X-ray attenuation. These properties enable them to
13 act as a new candidate for NIRF/CT/MR imaging applications.

14 3.4. *In vitro* cellular uptake

15 The cellular internalization of GNCNs and GNCs in A549 cells was quantified and
16 visually analyzed by flow cytometry (FCM) and confocal laser scanning microscopy
17 (CLSM), respectively (Fig.6). As shown in Fig. 6A, blue fluorescence was used to
18 localize the cell nuclei using Hoechst 33342 dye, while the GNCNs and GNCs were
19 detected by their intrinsic red fluorescence. Similarly to the behaviors of GNCs, the
20 GNCNs were mainly accumulated in the cytoplasm after endocytosis [24]. The
21 efficiency of the uptake of the GNCNs and GNCs in A549 cells was clearly increased
22 with a prolonged incubation time. For the GNCs, only a slight red fluorescence was
23 detected, after 4 h of incubation with the A549 cells, implying that a small quantity of
24 GNCs were internalized into the cells. On the other hand, a relatively strong red
25 fluorescence already appeared in the cytoplasm after the A549 cells were treated with
26 the GNCNs for 4 h. This phenomena was confirmed by the results of FCM (Fig.6B and
27 Fig.6C), where the mean fluorescence intensity of the A549 cells treated with the
28 GNCNs was 2.9 times higher than that of the GNCs incubated groups (Fig.6B). When
29 the incubation time was prolonged to a total of 10 h, the amount of internalized GNCs

1 slightly increased. Under the physiological pH range, the surface zwitterionization of
2 the GNCs may reduce the cellular affinity of GNCs, which may be the cause of the
3 lower efficiency in the cellular uptake [29, 56]. In contrast, a remarkable increase of red
4 fluorescence was detected in the cytoplasm of A549 cells after prolonging the
5 incubation time with GNCNs to 10 h, which indicated a clear uptake enhancement of
6 GNCNs compared with GNCs. One explanation of the increase in the cellular uptake of
7 GNCNs may be due to the changes in their surface upon addition of Gd^{3+} ions. In this
8 way, the linkage of the negatively charged carboxylic groups to the Gd^{3+} ions may
9 induce the nanoparticles to change from a zwitterionic to a non-zwitterionic surface and
10 also change their surface charge [57, 58]. Additionally, the mean fluorescence of the
11 cells treated with GNCNs measured by FCM was approximately 5.1-fold higher than
12 the corresponding cells incubated with GNCs, after being incubated for 10 hours
13 (Fig.6B). Overall, the results of CLSM were consistent with those obtained by FCM,
14 which suggested that the assembled GNCNs would improve the cell internalization of
15 GNCs. More importantly, ICP-MS analysis was also carried out to quantify the
16 intracellular content element of Au in A549 cells treated with GNCNs or GNCs after 4 h
17 and 10 h of treatment, respectively. The results further proved that the GNCNs exhibited
18 an excellent cellular uptake efficiency, compared to GNCs (Fig. S7).

19 3.5. *In vitro multi-modality imaging of cancer cells*

20 The multi-modality imaging ability of GNCNs was also explored in this study
21 using A549 cancer cells. The cells were cultivated with GNCs or GNCNs at different Au
22 or Gd^{3+} ion concentrations for 10 h before performing the multi-modality imaging.
23 Their CT/MR/NIRF imaging capabilities were quantified by measuring the CT value,
24 signal to noise ratio (SNR) and average fluorescence intensity, respectively. For the
25 T1-weighted MRI, an obvious increase was observed in both the brightness and the
26 signal to noise ratio (SNR) of T1-weighted cells MR images of GNCNs with the
27 increase of the Gd^{3+} ions concentration (Fig. S8A and S8B), which were remarkably
28 higher than those of PBS-incubated controls. Similarly to the T1-weighted MRI, the
29 NIRF imaging ability of GNCNs or GNCs depends on the concentration of Au (Fig.

1 S9A). The average fluorescence intensity of the cells treated with GNCNs was higher
2 than that of GNCs treated groups at the same Au concentrations, suggesting that the
3 GNCNs were easier to uptake by A549 cells than that of GNCs (Fig. S9B). Unlike with
4 MR and NIRF images of GNCNs treated cells, the brightness difference of the CT
5 images of the cells treated with GNCNs or GNCs was not easily distinguishable by
6 naked eye at various of Au concentrations (Fig. S8C) [8, 18]. Therefore, the CT values
7 of the GNCs and GNCNs treated cells were measured with the manufacture's standard
8 display program to detect the cells CT imaging effect of GNCs and GNCNs. As shown
9 in Fig. S8D, the CT values of cells treated with either GNCNs or GNCs increased with
10 the Au concentrations. A higher CT value was observed in the GNCNs treated cells than
11 in the GNCs treated ones, confirming the enhancement of the cells uptake efficiency
12 and the high X-ray attenuation property of GNCNs. The above conclusions were
13 verified by ICP-MS results, in which the Au content in A549 cells treated with GNCNs
14 was higher than that of GNCs at different Au concentrations after 10 h incubation (Fig.
15 S10A).

16 *3.6. In vivo tumor multi-modality imaging*

17 To explore the possibility of GNCNs as an imaging contrast agent for clinical
18 cancer diagnosis, the potential performance of GNCNs for multi-modality imaging was
19 carefully evaluated by applying MR/CT/NIRF imaging techniques in mouse models
20 with A549 xenografted tumor. For T1-weighted MRI, Fig. 7A showed that the
21 brightness of the tumor areas remarkably heightened after injection of GNCNs. The
22 quantified T1-weighted MRI signal intensity based on signal to noise ratio (SNR)
23 approximately increased one time at 20 min post-injection in the tumor area, and the
24 higher MRI signal lasted for 60 min (Fig. 7B). These observations suggested that the
25 GNCNs can rapidly accumulate in the tumor area thanks to the passive EPR effect [59].
26 Thus, there is no remarkable influence on the application of the GNCNs for
27 multi-modality cancer diagnosis, even if the selectivity of GNCNs towards cancer cells
28 was low (Fig S10B). Meanwhile, CT imaging of the tumor area exhibited a remarkable
29 contrast enhancement as well as T1-weighted MRI results after intravenous injection of

1 GNCNs or GNCs, which would be attributed to entire diffusion of the nanoparticles in
2 the tumor via EPR effect (Fig. 7C and Fig. S11). Moreover, the CT value of the tumor
3 area also reached a maximum at 20 min post-injection. Nevertheless, the CT value of
4 the tumor area was higher with GNCNs than with GNCs at the same time points,
5 inferring that the GNCNs possess a better CT imaging ability than GNCs *in vivo* (Fig.
6 7D).

7 By utilizing the intrinsic red-emitting ability of the GNCs under laser irradiation,
8 the GNCNs and the GNCs were used in NIRF imaging applications. After intratumoral
9 injection, the amounts of GNCNs or GNCs accumulated in the tumor areas were tested
10 by analyzing the fluorescence signal intensity distribution around the tumors (Fig. 8A
11 and B). The enhanced signal and intensity around the tumors of GNCNs treated mice
12 post-injection (0 h) may be attributed to the high luminescence intensity of GNCNs,
13 which was higher than that of free GNCs at the same Au concentrations. Moreover, the
14 reduction of the fluorescence signal intensity around the tumor at 2, 6, 12 and 24 hours
15 post-injection was much slower in the case of the mice injected with GNCNs than the
16 corresponding results of the GNCs. These observations confirmed the results of CT/MR
17 imaging, further suggesting that the assembly of GNCNs possess tumor longer retention
18 times than that of GNCs by the passive targeting of EPR effect. Moreover, *ex vivo* NIRF
19 imaging (Fig. 8C and D) results indicated that most of the GNCNs were accumulated in
20 the tumor, followed by liver, kidney and lung, 24 h after intratumoral injection of
21 GNCNs. Meanwhile, the averaged fluorescence intensity of the GNCNs in the tumor
22 sites was much higher than that of free GNCs. To sum up, the inescapable conclusion is
23 that the prepared GNCNs have a great potential as multifunction contrast agent for
24 clinical cancer MR/ CT /NIRF imaging.

25 The biodistribution of GNCNs based on ICP-MS (Fig. S12) revealed that the
26 elemental distribution of Au in the different organs was similar to that of Gd³⁺ ions in
27 the mice post-injection of GNCNs, further suggesting that the GNCNs were formed by
28 the assimilation of GNCs with Gd³⁺ ions rather than as a result of a mixture of the
29 GNCs and Gd³⁺ ions. The ICP-MS results also indicated a fast urine elimination of
30 GNCNs, as the GNCNs were significantly accumulated in the kidney post-injection and

1 were almost cleared from the kidney with a prolonged circulation time of 6 h. Future
2 study is needed to improve the surface modification of the GNCNs aiming to increase
3 their blood circulation time. Moreover, a small amount of Au and Gd remained in heart,
4 liver, spleen, and lung post-injection, suggesting a low uptake of the GNCNs by the
5 Reticulo-Endothelial System (RES) tissues and that the GNCNs were not significantly
6 retained in the lung [54]. These observations indicated that the GNCNs are safe for *in*
7 *vivo* biomedical imaging applications.

8 3.7. *In vivo* security evaluation

9 The *in vivo* security evaluation of imaging contrast agents is crucial for their use in
10 clinical disease diagnosis. In this study, the body weight change, blood biochemistry
11 analysis and HE-stained histology were performed to assess the *in vivo* safety of the
12 GNCNs as contrast agents for multi-modality imaging. The HE stained slices of main
13 organs (e.g., lung, heart, liver, spleen and kidney) showed no noticeable abnormality or
14 lesion after 21 days post-injection of GNCNs (Fig. S13). The weight change is one of
15 the main indicators of organism intoxication [39]. As shown in Fig. S14, no significant
16 body weight loss was detected in the GNCNs treated mice and there was no death of
17 mice in the whole time period of the experiment. Moreover, to further verify whether
18 the GNCNs would cause damage of the liver and kidney, where the most of exogenous
19 substances are metabolized and cleared, a blood biochemistry of main liver and kidney
20 indicators was analyzed 7 and 21 days after intravenously injection of GNCNs. As
21 shown in Fig. S15, neither the liver function indicators nor the kidney function revealed
22 any significant toxicity symptoms in the GNCNs injected groups compared to that of
23 the normal control groups [40]. All of the abovementioned data demonstrated that the
24 GNCNs would not induce any injury to the organs and that they can be safely applied in
25 clinic cancer imaging as contrast agents.

26 4. Conclusion

27 In this study, the gold nanoclusters (GNCs) were assembled into monodisperse
28 spherical particles (GNCNs) in aqueous solution for enhanced tumor multi-modality

1 imaging by selectively inducing electrostatic interactions between trivalent cations of
2 gadolinium and negatively-charged carboxyl groups on the GNCs. By this simple,
3 time-saving assembly approach, the Gd^{3+} ions can be chelated into the GNCNs without
4 using molecular gadolinium chelates, giving GNCNs regular morphology and enhanced
5 photoluminescence properties under mild conditions. Compared with free GNCs, the
6 resulting GNCNs have good biocompatibility both *in vitro* and *in vivo* and can be easily
7 internalized by the A549 cells. With the co-existence of GNCs and Gd^{3+} ions, the
8 GNCNs could be used as a multifunctional nanoplatform for NIRF/CT/MR imaging of
9 A549 cancer cells *in vitro* and of xenografted A549 tumor models *in vivo*. Therefore, the
10 multifunctional GNCNs hold great promise in clinic cancer diagnosis. In addition, this
11 study may provide some guidelines for the assembly of other hydrophilic ultrasmall
12 nanoparticles modified with carboxyl-containing surfaces, such as carbon dots and
13 quantum dots. Such guidelines have the potential to broaden the application of these
14 ultrasmall nanoparticles in cancer diagnosis.

15 **Supporting Information**

16 Supporting Information is available from the Wiley Online Library or from the
17 author.

18 **Acknowledgments**

19 This work is supported by the National Key Basic Research Program (973 Project)
20 (Project No. 2015CB931802), the National Natural Scientific Foundation of China
21 (Grant Nos. 81401458, 81225010, 81028009, and 31170961), the 863 project of China
22 (Project No. 2014AA020701), and the Shanghai Science and Technology Fund (Grant
23 Nos. 14ZR1432400 and 13NM1401500).


24

References

- [1] Sandu N, Pöpperl G, Toubert M-E, Spiriev T, Arasho B, Orabi M, et al. Current molecular imaging of spinal tumors in clinical practice. *Mol Med* 2011;17:308-16.
- [2] Zhang J, Li C, Zhang X, Huo S, Jin S, An F-F, et al. In vivo tumor-targeted dual-modal fluorescence/CT imaging using a nanoprobe co-loaded with an aggregation-induced emission dye and gold nanoparticles. *Biomaterials*. 2015;42:103-11.
- [3] Guo W, Sun X, Jacobson O, Yan X, Min K, Srivatsan A, et al. Intrinsically radioactive [⁶⁴Cu] CuInS/ZnS quantum dots for PET and optical imaging: improved radiochemical stability and controllable cerenkov luminescence. *ACS nano*. 2015;9:488-95.
- [4] Peng C, Qin J, Zhou B, Chen Q, Shen M, Zhu M, et al. Targeted tumor CT imaging using folic acid-modified PEGylated dendrimer-entrapped gold nanoparticles. *Polym Chem*. 2013;4:4412-24.
- [5] Wen S, Zhao Q, An X, Zhu J, Hou W, Li K, et al. Multifunctional PEGylated Multiwalled Carbon Nanotubes for Enhanced Blood Pool and Tumor MR Imaging. *Adv Healthcare Mater*. 2014;3:1568-77.
- [6] Smith AM, Nie S. Next-generation quantum dots. *Nat Biotechnol*. 2009;27:732-33.
- [7] Lee J-H, Huh Y-M, Jun Y-w, Seo J-w, Jang J-t, Song H-T, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. *Nat Med*. 2007;13:95-9.
- [8] Chen Q, Li K, Wen S, Liu H, Peng C, Cai H, et al. Targeted CT/MR dual mode imaging of tumors using multifunctional dendrimer-entrapped gold nanoparticles. *Biomaterials*. 2013;34:5200-9.
- [9] Gong H, Dong Z, Liu Y, Yin S, Cheng L, Xi W, et al. Engineering of Multifunctional Nano - Micelles for Combined Photothermal and Photodynamic Therapy Under the Guidance of Multimodal Imaging. *Adv Funct Mater*. 2014;24:6492-502.
- [10] Wu Y, Sun Y, Zhu X, Liu Q, Cao T, Peng J, et al. Lanthanide-based nanocrystals as dual-modal probes for SPECT and X-ray CT imaging. *Biomaterials*. 2014;35:4699-705.
- [11] Wen S, Li K, Cai H, Chen Q, Shen M, Huang Y, et al. Multifunctional dendrimer-entrapped gold nanoparticles for dual mode CT/MR imaging applications. *Biomaterials*. 2013;34:1570-80.
- [12] Petersen AL, Henriksen JR, Binderup T, Elema DR, Rasmussen PH, Hag AM, et al. In vivo evaluation of PEGylated ⁶⁴Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT. *Eur J Nucl Med Mol Imaging*. 2016;43:941-52.
- [13] Tian G, Zheng X, Zhang X, Yin W, Yu J, Wang D, et al. TPGS-stabilized NaYbF₄: Er upconversion nanoparticles for dual-modal fluorescent/CT imaging and anticancer drug delivery to overcome multi-drug resistance. *Biomaterials*. 2015;40:107-16.
- [14] Zhao L, Wen S, Shi X, Zhao J. ^{99m}Tc labeled multifunctional polyethylenimine-entrapped gold nanoparticles for dual mode SPECT and CT imaging. *J Nucl Med*. 2016;57:1091-91.
- [15] Zhou C, Hao GY, Thomas P, Liu JB, Yu MX, Sun SS, et al. Near-Infrared Emitting Radioactive Gold Nanoparticles with Molecular Pharmacokinetics. *Angew Chem-Int Edit*. 2012;51:10118-22.
- [16] Hu D-H, Sheng Z-H, Zhang P-F, Yang D-Z, Liu S-H, Gong P, et al. Hybrid gold-gadolinium nanoclusters for tumor-targeted NIRF/CT/MRI triple-modal imaging in vivo. *Nanoscale*. 2013;5:1624-8.
- [17] Ye E, Win KY, Tan HR, Lin M, Teng CP, Mlayah A, et al. Plasmonic Gold Nanocrosses with Multidirectional Excitation and Strong Photothermal Effect. *J Am Chem Soc*. 2011;133:8506-9.
- [18] Li J, Hu Y, Yang J, Wei P, Sun W, Shen M, et al. Hyaluronic acid-modified Fe₃O₄@ Au core/shell nanostars for multimodal imaging and photothermal therapy of tumors. *Biomaterials*. 2015;38:10-21.
- [19] Chen Y-S, Choi H, Kamat PV. Metal-cluster-sensitized solar cells. A new class of thiolated gold sensitizers

- delivering efficiency greater than 2%. *J Am Chem Soc.* 2013;135:8822-5.
- [20] Zhu Y, Qian H, Zhu M, Jin R. Thiolate - Protected Au Nanoclusters as Catalysts for Selective Oxidation and Hydrogenation Processes. *Adv Mater.* 2010;22:1915-20.
- [21] Chen L-Y, Wang C-W, Yuan Z, Chang H-T. Fluorescent gold nanoclusters: recent advances in sensing and imaging. *Anal Chem.* 2014;87:216-29.
- [22] Yahia-Ammar A, Sierra D, Mérola F, Hildebrandt N, Le Guével X. Self-Assembled Gold Nanoclusters for Bright Fluorescence Imaging and Enhanced Drug Delivery. *ACS nano.* 2016;10:2591-9.
- [23] Le Guével X. Recent advances on the synthesis of metal quantum nanoclusters and their application for bioimaging. *IEEE J Sel Top Quantum Electron.* 2014;20:6801-12.
- [24] Zhang C, Li C, Liu Y, Zhang J, Bao C, Liang S, et al. Gold Nanoclusters - Based Nanoprobes for Simultaneous Fluorescence Imaging and Targeted Photodynamic Therapy with Superior Penetration and Retention Behavior in Tumors. *Adv Funct Mater.* 2015;25:1314-25.
- [25] Fernández TD, Pearson JR, Leal MP, Torres MJ, Blanca M, Mayorga C, et al. Intracellular accumulation and immunological properties of fluorescent gold nanoclusters in human dendritic cells. *Biomaterials.* 2015;43:1-12.
- [26] Zheng J, Zhou C, Yu M, Liu J. Different sized luminescent gold nanoparticles. *Nanoscale.* 2012;4:4073-83.
- [27] Xie J, Zheng Y, Ying JY. Protein-directed synthesis of highly fluorescent gold nanoclusters. *J Am Chem Soc.* 2009;131:888-9.
- [28] Shen Z, Duan H, Frey H. Water - soluble fluorescent Ag nanoclusters obtained from multiarm star poly (acrylic acid) as “molecular hydrogel” templates. *Adv Mater.* 2007;19:349-52.
- [29] Zhang C, Zhou Z, Qian Q, Gao G, Li C, Feng L, et al. Glutathione-capped fluorescent gold nanoclusters for dual-modal fluorescence/X-ray computed tomography imaging. *J Mater Chem B.* 2013;1:5045-53.
- [30] Wu Z, Jin R. Stability of the Two Au– S Binding Modes in Au₂₅ (SG) 18 Nanoclusters Probed by NMR and Optical Spectroscopy. *ACS nano.* 2009;3:2036-42.
- [31] Guan G, Low M, Liu S, Cai Y, Zhang S, Geng D, et al. Destabilization of Thiolated Gold Clusters for the Growth of Single - Crystalline Gold Nanoparticles and Their Self - Assembly for SERS Detection. *Part Part Syst Charact.* 2015;32:588-95.
- [32] Zhu M, Qian H, Jin R. Thiolate-protected Au₂₀ clusters with a large energy gap of 2.1 eV. *J Am Chem Soc.* 2009;131:7220-1.
- [33] Zhang XD, Chen J, Luo Z, Wu D, Shen X, Song SS, et al. Enhanced Tumor Accumulation of Sub - 2 nm Gold Nanoclusters for Cancer Radiation Therapy. *Adv Healthcare Mater.* 2014;3:133-41.
- [34] Aldeek F, Muhammed MH, Palui G, Zhan N, Mattoussi H. Growth of highly fluorescent polyethylene glycol-and zwitterion-functionalized gold nanoclusters. *ACS nano.* 2013;7:2509-21.
- [35] Shang L, Stockmar F, Azadfar N, Nienhaus GU. Intracellular thermometry by using fluorescent gold nanoclusters. *Angew Chem-Int Edit.* 2013;52:11154-7.
- [36] Song X, Liang C, Gong H, Chen Q, Wang C, Liu Z. Photosensitizer - Conjugated Albumin– Polypyrrole Nanoparticles for Imaging - Guided In Vivo Photodynamic/Photothermal Therapy. *Small.* 2015;11:3932-41.
- [37] Zhou J, Lu Z, Shan G, Wang S, Liao Y. Gadolinium complex and phosphorescent probe-modified NaDyF₄ nanorods for T₁- and T₂-weighted MRI/CT/phosphorescence multimodality imaging. *Biomaterials.* 2014;35:368-77.
- [38] Yao Q, Luo Z, Yuan X, Yu Y, Zhang C, Xie J, et al. Assembly of nanoions via electrostatic interactions: ion-like behavior of charged noble metal nanoclusters. *Sci Rep.* 2014;4:3848.
- [39] Hou W, Xia F, Alves CS, Qian X, Yang Y, Cui D. MMP2-targeting and redox-responsive PEGylated chlorin e6 nanoparticles for cancer near-infrared imaging and photodynamic therapy. *ACS Appl Mater Interfaces.* 2016;8:1447-57.
- [40] Zhang C, Zhou Z, Zhi X, Ma Y, Wang K, Wang Y, et al. Insights into the distinguishing stress-induced cytotoxicity of chiral gold nanoclusters and the relationship with GSTP1. *Theranostics.* 2015;5:134-149.

- [41] Pirie NW, Pinhey KG. The titration curve of glutathione. *J Biol Chem.* 1929;84:321-33.
- [42] Ye D-X, Ma Y-Y, Zhao W, Cao H-M, Kong J-L, Xiong H-M, et al. ZnO-Based Nanoplatfoms for Labeling and Treatment of Mouse Tumors without Detectable Toxic Side Effects. *ACS nano.* 2016;10:4294-300.
- [43] Luo Z, Yuan X, Yu Y, Zhang Q, Leong DT, Lee JY, et al. From aggregation-induced emission of Au (I)-thiolate complexes to ultrabright Au (0)@ Au (I)-thiolate core-shell nanoclusters. *J Am Chem Soc.* 2012;134:16662-70.
- [44] Gao Z, Lukyanov AN, Singhal A, Torchilin VP. Diacyllipid-polymer micelles as nanocarriers for poorly soluble anticancer drugs. *Nano Lett.* 2002;2:979-82.
- [45] Mou F, Xu L, Ma H, Guan J, Chen D-r, Wang S. Facile preparation of magnetic γ -Fe₂O₃/TiO₂ Janus hollow bowls with efficient visible-light photocatalytic activities by asymmetric shrinkage. *Nanoscale.* 2012;4:4650-7.
- [46] Ye E, Regulacio MD, Bharathi MS, Pan H, Lin M, Bosman M, et al. An experimental and theoretical investigation of the anisotropic branching in gold nanocrosses. *Nanoscale.* 2016;8:543-52.
- [47] Schmidbaur H. Ludwig Mond lecture. High-carat gold compounds. *Chem Soc Rev.* 1995;24:391-400.
- [48] Ito H, Saito T, Oshima N, Kitamura N, Ishizaka S, Hinatsu Y, et al. Reversible mechanochromic luminescence of [(C₆F₅Au)₂(μ -1, 4-Diisocyanobenzene)]. *J Am Chem Soc.* 2008;130:10044-5.
- [49] Hong Y, Lam JW, Tang BZ. Aggregation-induced emission. *Chem Soc Rev.* 2011;40:5361-88.
- [50] Ghosh SK, Pal T. Interparticle coupling effect on the surface plasmon resonance of gold nanoparticles: from theory to applications. *Chem Rev* 2007;107:4797-862.
- [51] Liu D, Wang Z, Jiang X. Gold nanoparticles for the colorimetric and fluorescent detection of ions and small organic molecules. *Nanoscale.* 2011;3:1421-33.
- [52] Md NS, Kim H-K, Park J-A, Chang Y, Kim T-J. Gold nanoparticles coated with Gd-chelate as a potential CT/MRI bimodal contrast agent. *Bull Korean Chem Soc.* 2010;31:1177-81.
- [53] Alric C, Taleb J, Duc GL, Mandon C, Billotey C, Meur-Herland AL, et al. Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging. *J Am Chem Soc.* 2008;130:5908-15.
- [54] Frangville C, Li Y, Billotey C, Talham DR, Taleb J, Roux P, et al. Assembly of double-hydrophilic block copolymers triggered by gadolinium ions: new colloidal MRI contrast agents. *Nano Lett.* 2016; 16:4069-73
- [55] Cheng Z, Thorek DL, Tsourkas A. Gadolinium - Conjugated Dendrimer Nanoclusters as a Tumor - Targeted T1 Magnetic Resonance Imaging Contrast Agent. *Angew Chem-Int Edit.* 2010;49:346-50.
- [56] Yu M, Zhou C, Liu J, Hankins JD, Zheng J. Luminescent gold nanoparticles with pH-dependent membrane adsorption. *J Am Chem Soc.* 2011;133:11014-7.
- [57] He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. *Biomaterials.* 2010;31:3657-66.
- [58] Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. *Int J Nanomedicine.* 2012;7:5577-91.
- [59] Bu L, Xie J, Chen K, Huang J, Aguilar ZP, Wang A, et al. Assessment and comparison of magnetic nanoparticles as MRI contrast agents in a rodent model of human hepatocellular carcinoma. *Contrast Media Mol Imaging.* 2012;7:363-72.



Scheme 1. Schematic illustration of gadolinium (Gd^{3+}) ions-mediated self-assembly of gold nanoclusters (GNCs) into monodisperse spherical nanoparticles (GNCNs) for multi-modality cancer diagnosis under mild conditions.




Fig. 1. Characterizations of the GNCNs. (A) TEM image of the GNCNs. (Inset) the amplified TEM image of the GNCNs. (B) HR-TEM image of the GNCNs. (C) SEM image of the GNCNs. (Inset) amplified SEM image of the GNCNs. (D) DLS curve shows the diameter distribution of the GNCNs.




Fig. 2. (A) STEM image of a typical assembly (GNCNs). (B–C) The mapping EDX analysis of distribution of Au (B) and Gd (C) elements in a typical assembly in (A). The insets in (B) and (C) display the elemental line-scanning EDX analysis of Au (red curve) and Gd (green curve), respectively. (D) Shows the superimposing image of (B) and (C). (E) Shows the EDX spectrum analysis of the content of the Au and Gd elements of the typical assembly in (A).




Fig. 3. (A) Fluorescence spectra of the GNCs and the GNCNs ($\lambda_{ex} = 520$ nm). (Inset) Digital pictures of GNCs (left) and GNCNs (right) dissolved in aqueous solution under UV(365 nm) excitation. (B) Colloid stability test of GNCNs in aqueous solution (mean \pm SD, n =3).




Fig. 4. (A) A549 cells viability measured by MTT assay after incubation with PBS (as control) and the GNCNs at different Au concentrations for 24 h and 48 h, respectively (mean \pm SD, $n = 3$). (B) Hemolytic activity of GNCNs at different Au concentrations. The bottom-right inset and the upper-right inset represent the photograph of HRBCs and the enlarged UV–Vis absorption of the supernatant after the blood incubation with water, PBS and GNCNs PBS solution at different Au concentrations for 2 h, respectively.




Fig. 5. X-ray attenuation property and T1 MR relaxometry of the GNCNs. (A) CT images and (B) X-ray attenuation intensity of GNCs, GNCNs and Omnipaque (O) at different Au or I concentrations, respectively. (C) T1-MR images of Gd-DTPA and GNCNs. (D) The linear fitting of the inverse T1 of Gd-DTPA and GNCNs as a function of Gd³⁺ ion concentration.




Fig. 6. Cellular uptake of GNCNs by A549 cells. (A) Confocal images of the A549 cells treated with GNCNs or GNCs for 4 and 10 h, respectively. Scale bar, 100 μ m. (B) Flow cytometry analysis of the A549 cells incubated with GNCNs or GNCs for 4 and 10 h, respectively. Mean: mean fluorescence of M2 subset. (C) The population distribution histogram of A549 cells with GNCs or GNCNs (mean \pm SD, n = 3).




Fig. 7. *In vivo* X-ray CT/MR imaging. (A) *In vivo* T1-weighted MR images of A549 tumor-bearing mice post intravenous injection of GNCNs at different time points. (B) T1 signal to noise ratio around the tumors of (A). (C) CT images of A549 tumors-bearing mice post intravenous injection of GNCs or GNCNs at different time points. (D) CT values around the tumors of (C). The arrows point indicate the location of the tumor area (mean \pm SD, n =3).




Fig. 8. *In vivo* NIRF imaging and biodistribution of the A549 tumor-bearing mice post intratumoral injection of GNCNs or GNCs. (A) *In vivo* time-dependent NIRF imaging of A549 tumor-bearing nude mice. (B) The average fluorescence signal intensities around the tumors of (A) (mean \pm SD, $n = 3$). (C) *In vitro* biodistribution of the extracted main organs and tumors at 24 h post intratumoral injection of GNCNs or GNCs. (D) The average fluorescence intensities of (C) (3 mice/group).